Case Study: Data corruption and security posture issues threaten a Clinical Research Company's operations
Industry: Life Sciences
Company Type: Clinical Research
The Challenge
This clinical research company was dealt a blow when a major data corruption issue threatened its ability to operate. The technology stack was outdated, and it was implemented without best practices. IT projects were misaligned with the company’s business objectives.
The Discovery
Boston BizTech discovered that the IT and security practices in place were incapable of passing an audit. The Technology stack was over 10 years old and had an insecure configuration that opened vulnerabilities to multiple concurrent cyber attacks. Additionally, various staff were being tricked into phishing scams thinking their CEO asked them to use their personal finances to purchase gift cards. The company could not meet the technology, security, and privacy standards required to win new high-profile clients.
The Solution
Boston BizTech architected an enterprise IT infrastructure and security implementation that fits and scales the technology stack to support the business for future growth. Our team constructed a new hybrid IT infrastructure (public cloud and on-prem servers) deployed with a modernized network incorporating best practices. Our team deployed information security solutions integrated with the new network infrastructure for simplified management and monitoring. We then created new IT, security, and data privacy SOPs aligned with NIST guidelines and compliant with FDA and GDPR regulations. Additionally, all staff received cybersecurity awareness training, and a security incident response program was initiated.
The Impact
A robust enterprise architecture was implemented and deployed properly as it would be in a Fortune 500 company. The IT department transitioned from operating in reactive mode, constantly fighting fires, to proactive mode, implementing solutions to win new business clients. Multiple audits were conducted and successfully passed, allowing multiple clinical trial deals to proceed with activation.